Abstract | BACKGROUND: METHODS: Sixty-three patients with DSM-IV schizophrenia or schizoaffective disorder (n = 61) or bipolar I disorder (n = 2) consecutively admitted to a state hospital, who were treated either with olanzapine (n = 35) or conventional antipsychotic agents (n = 28) by physician choice, were enrolled in the study. The severity and frequency of tardive dyskinetic symptoms using the Abnormal Involuntary Movement Scale were assessed in the two medication groups at baseline, 8 weeks, and 6 months. RESULTS: There were statistically significant reductions in the prevalence and severity of dyskinetic symptoms at 8 weeks and 6 months for the group treated with olanzapine but not for those treated with conventional agents. CONCLUSIONS: These preliminary data suggest that olanzapine may be a treatment option for subjects with tardive dyskinesia. However, the question whether olanzapine treats, ameliorates, or masks preexisting tardive dyskinesia was difficult to answer, as no dosage reduction or withdrawal was undertaken.
|
Authors | Jaspreet S Brar, Haranath Parepally, Lokaranjit Chalasani, Aziz Gopalani, Nicole Appel, K N Roy Chengappa |
Journal | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
(Ann Clin Psychiatry)
2008 Jul-Sep
Vol. 20
Issue 3
Pg. 139-44
ISSN: 1547-3325 [Electronic] United States |
PMID | 18633740
(Publication Type: Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Benzodiazepines
- Olanzapine
|
Topics |
- Adult
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Benzodiazepines
(adverse effects, therapeutic use)
- Bipolar Disorder
(diagnosis, drug therapy)
- Cross-Sectional Studies
- Dyskinesia, Drug-Induced
(diagnosis, epidemiology, etiology)
- Female
- Follow-Up Studies
- Hospitalization
- Humans
- Male
- Middle Aged
- Neurologic Examination
(drug effects)
- Olanzapine
- Psychotic Disorders
(diagnosis, drug therapy)
- Schizophrenia
(drug therapy)
|